Radiopharm Theranostics RADX
NASDAQ RADX
$1.42 -0.06 (-4.05%)
At close: Oct 2, 2026 · 4:00 PM EDT

Radiopharm Theranostics (RADX) Income towards Parent Company (2023 - 2026)

Updated

Radiopharm Theranostics' Income towards Parent Company came in at -$386,785 for FY2026 (year ended Jun 30, 2026), compared with -$38.34 million in FY2025.

Analysis

Radiopharm Theranostics (RADX) Income towards Parent Company (2023 - 2026) Analysis & Trends

Going back to FY2023, Radiopharm Theranostics' Income towards Parent Company data covers 4 fiscal years.

  • The five-year range for annual Income towards Parent Company is -$38.34 million (FY2025) to -$315,996 (FY2024).
  • Per Business Quant, earlier fiscal years put Income towards Parent Company at -$38.34 million in FY2025, -$315,996 in FY2024 and -$34.61 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Radiopharm Theranostics 5.03 Bn 5.00 Bn 186,835.86
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -40.40 Mn
Jun 30, 2025 -38.34 Mn
Jun 30, 2024 -47.95 Mn
Jun 30, 2023 -34.61 Mn
API Access

Radiopharm Theranostics Income towards Parent Company API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-towards-parent-company&ticker=RADX&period=max&api_key=YOUR_API_KEY